Multiple Sclerosis: Tecfidera (BG-12), tBHQ, SFN and Protandim Compared

The study by J. Lim, S. van der Pol, J. Drexhage, E. de Vries, J. van Horssen (Amsterdam, NL) investigates the potential that four different Nrf2 activators (BG-12, tBHQ, SFN and protandim) had to boost antioxidant enzyme expression in oligodendrocytes and protect them from reactive oxygen species (ROS)-mediated cell death.

In a previous post entitled, “Multiple Sclerosis, Oxidative Stress and NRF2: What you Need to Know!” The potential benefits of NRF2 activation on Multiple Sclerosis (MS) were examined.

 

This post updates the previous post to include findings from a paper presented to 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (Amsterdam, The Netherlands 2011)

 

The study by J. Lim, S. van der Pol, J. Drexhage, E. de Vries, J. van Horssen (Amsterdam, NL) investigates the potential that four different Nrf2 activators (BG-12, tBHQ, SFN and protandim) had to boost antioxidant enzyme expression in oligodendrocytes and protect them from reactive oxygen species (ROS)-mediated cell death. View the MS & NRF2 study summary.

 

To quote from the summary, “BG-12, tBHQ, SFN and protandim are well-tolerated and strongly induce Nrf2-driven antioxidant enzyme production in oligodendrocytes, with protandim showing the most potent induction.”

Sign Up for Our Newsletter

Augusta University Discovers How Nrf2 Activator Preserves Sight in Retinal Degeneration Model
New Protandim Study – International Formula Impact on Oxidative Stress
Reversal of persistent fibrosis in aging by targeting nox4-Nrf2 redox imbalance – Sciencemag.org